Breast Cancer

Latest News

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.

Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer
Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer

August 6th 2022

Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer
Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer

May 9th 2022

FDA Approves Enhertu for Use in Metastatic Breast Cancer
FDA Approves Enhertu for Use in Metastatic Breast Cancer

May 5th 2022

Contributor: Helping Women of Color Achieve a Healthier Future
Contributor: Helping Women of Color Achieve a Healthier Future

April 27th 2022

Video Interviews
Podcasts

More News

© 2023 MJH Life Sciences
AJMC®
All rights reserved.